Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SK bioscience Co.,Ltd. (302440.KS)
Seongnam-si, KR
SK bioscience Co.,Ltd. is a pharmaceutical firm focused on the discovery, development, production, and worldwide commercialization of vaccines and other biopharmaceutical products. Its current range of marketed vaccines includes Skycellflu, a cell-cultured influenza vaccine, along with its pre-filled syringe version, Skycellflu 4-ga. The company also provides pneumococcal vaccines for both adults and children, Skyzoster for shingles, and Sky Baricella, designed to prevent chickenpox in pediatric patients. Beyond its existing portfolio, SK bioscience maintains an active research and development pipeline. Several candidates have completed Phase 2 clinical trials, including an oral rotavirus vaccine, a cervical cancer vaccine, and a low-cost pneumococcal vaccine. A distinct rotavirus vaccine is currently in Phase 3 trials in Africa, while a next-generation pneumococcal vaccine is undergoing Phase 2 trials in the United States. Other projects in development include a typhoid conjugate vaccine and a COVID-19 vaccine, which is progressing through Phase 1 and Phase 1/2 clinical studies. The company was established in 2018 and is headquartered in Seongnam-si, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.56% | -5.18% | -2.02% | -18.84% | -25.86% | -14.27% | +4.05% | -47.24% | -71.42% | -75.65% | -75.65% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 2 | -1 |
| Sell | 2 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Biotechnology: +1.6%+143.5% ★ Q1'26: +9.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-2.4% Q1'26: -348.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1.0% Q1'26: -3.7% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-23.2% Q1'26: +26.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-9.5% ★ Q1'26: +8.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.1% ★ Q1'26: -0.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-7.79× Q1'26: 2.64× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 5 Rev. Ana. 3 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
929.00B
est: 930.00B (-0.1%)
|
456.73B
est: 521.89B (-12.5%)
|
369.51B
est: 336.64B (+9.8%)
|
267.55B
est: 232.92B (+14.9%)
|
651.37B
est: 639.88B (+1.8%)
|
738.96B
737.25B – 740.67B
+15.5% YoY
|
790.99B
741.00B – 858.34B
+7.0% YoY
|
902.85B
872.72B – 943.09B
+14.1% YoY
|
| EBITDA |
493.00B
est: 213.04B (+131.4%)
|
171.43B
est: 119.55B (+43.4%)
|
43.49B
est: 77.12B (-43.6%)
|
-36.20B
est: 37.07B (-197.6%)
|
-60.31B
est: 101.85B (-159.2%)
|
117.62B
117.35B – 117.89B
+15.5% YoY
|
125.90B
117.94B – 136.62B
+7.0% YoY
|
143.70B
138.91B – 150.11B
+14.1% YoY
|
| EBIT |
474.56B
est: 132.84B (+257.2%)
|
144.19B
est: 74.55B (+93.4%)
|
8.73B
est: 48.09B (-81.9%)
|
-85.42B
est: 13.89B (-715.0%)
|
-151.33B
est: 38.16B (-496.5%)
|
44.07B
43.97B – 44.17B
+15.5% YoY
|
47.17B
44.19B – 51.19B
+7.0% YoY
|
53.84B
52.05B – 56.24B
+14.1% YoY
|
| Net Income |
355.14B
est: 384.40B (-7.6%)
|
122.45B
est: 156.64B (-21.8%)
|
22.32B
est: 6.21B (+259.4%)
|
-53.88B
est: -65.13B (+17.3%)
|
-56.17B
est: -41.40B (-35.7%)
|
-87.45B
-92.17B – -82.72B
-111.2% YoY
|
-70.73B
-91.00B – -59.67B
+19.1% YoY
|
-27.45B
-29.04B – -26.26B
+61.2% YoY
|
| SGA |
15.74B
est: 66.05B (-76.2%)
|
27.32B
est: 37.06B (-26.3%)
|
25.35B
est: 23.91B (+6.0%)
|
40.90B
est: 13.89B (+194.4%)
|
—
est: 38.16B (-100.0%)
|
44.07B
43.97B – 44.18B
+15.5% YoY
|
47.18B
44.20B – 51.19B
+7.0% YoY
|
53.85B
52.05B – 56.25B
+14.1% YoY
|
| EPS |
4,642.34
est: 4,967.36 (-6.5%)
|
1,596.18
est: 2,024.14 (-21.1%)
|
291.00
est: 80.24 (+262.7%)
|
-700.16
est: -832.81 (+15.9%)
|
-718.26
est: -529.40 (-35.7%)
|
-1,118.12
-1,178.60 – -1,057.65
-111.2% YoY
|
-904.44
-1,163.61 – -763.01
+19.1% YoY
|
-351.01
-371.35 – -335.78
+61.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jae-Yong Ahn | Chief Executive Officer, President & Director | 4B | male |
| Ki-seok Song | Value Innovation Director | 621M | — |
| Sally Choe | Head of Global Clinical Development & Regulatory Affairs | 613M | — |
| Jin-seon Park | Head of Marketing & Business Development | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 302440.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
